corticotropin-releasing factor

Corticotropin-releasing factor (human) acetate 刺激垂体前叶合成和分泌促肾上腺皮质激素。

Human CRF acetate is a chemical compound that effectively stimulates the synthesis and secretion of adrenocorticotropin in the anterior pituitary.

Corticotropin-releasing factor human (Human CRF; Human corticotropin-releasing factor) is an immunomodulatory neuropeptide that releases ACTH from the anterior pituitary and stimulates the sympathetic nervous system and adrenal medulla.

α-Helical Corticotropin Releasing Factor (9-41) 为corticotropin releasing factor (CRF)的拮抗剂，具有降低体内血浆生长激素(GH)水平的功能。

a-Helical Corticotropin Releasing Factor (12-41)，一种含有30个氨基酸的α螺旋促肾上腺皮质激素释放因子 激素类似物。作为下丘脑激素的促肾上腺皮质激素释放因子 (CRF) 能促进肾上腺皮质激素 (ACTH) 分泌，而a-Helical Corticotropin Releasing Factor (12-41) 则抑制该刺激效应。

[DPro5] Corticotropin Releasing Factor, human, rat 是人类和大鼠促肾上腺皮质激素释放因子 激素 R2 的选择性激动剂。作为一种下丘脑激素，促肾上腺皮质激素释放因子 (CRF) 能够促进肾上腺皮质激素 (ACTH) 和 β-内啡肽的分泌。值得注意的是，[DPro5] Corticotropin Releasing Factor, human, rat 并不触发典型的焦虑反应，而是能调控大鼠的学习与记忆过程。

[Met(O)21] Corticotropin Releasing Factor, ovine 是一种从绵羊下丘脑提取物中分离出的促肾上腺皮质激素释放因子(CRF)。该因子为一类下丘脑激素，主要功能为促进肾上腺皮质激素(ACTH)的分泌。

[Tyr0] Corticotropin Releasing Factor, ovine 是从绵羊分离的促肾上腺皮质激素释放因子 激素。该因子（CRF）为下丘脑激素，能激发促肾上腺皮质激素（ACTH）及β-内啡肽的释放。

Urocortin, human (Human urocortin I) 是由 40 个氨基酸组成的神经多肽，是选择性 CRF2受体激动剂，作用于 hCRF1(Ki:0.4 nM)、rCRF2α(Ki:0.3 nM)、 mCRF2β(Ki:0.5 nM)。

Crinecerfont (SSR-125543) 是促肾上腺皮质激素释放因子 1 受体 (CRF1) 的特异性拮抗剂，可用于经典先天性肾上腺增生的研究。

Pivagabine (CXB-722) 是疏水性 4-氨基丁酸的衍生物，具有神经调节活性。它可穿透大鼠的血脑屏障，拮抗足部休克对大鼠脑中 GABAA 受体功能和促肾上腺皮质激素释放因子 (CRF) 浓度的影响。

NVS-CRF38 is an antagonist of corticotropin-releasing factor receptor 1 (CRF1).

Emicerfont is an antagonist of the corticotropin-releasing factor type 1 receptor (IC50: 66 nM).

Pexacerfont (BMS-562086) 是一种选择性的促肾上腺皮质激素释放因子 (CRF1) 受体拮抗剂，作用于人 CRF1 受体，IC50 为 6.1±0.6 nM。

Vasopressin-d5 TFA为Vasopressin-d5的TFA盐形式，并作为Vasopressin的同位素标记物。Vasopressin本身是一种在下丘脑中部合成的环状九肽。它参与下丘脑-垂体-肾上腺轴中的功能，通过加强对促皮质素释放因子的刺激，从而调控垂体的促皮质素分泌。此外，Vasopressin还能作为神经递质，通过与特定的G蛋白偶联受体相结合来发挥作用。

Antalarmin hydrochloride 是促肾上腺皮质激素释放因子 1 (CRF1) 的拮抗剂。 Antalarmin hydrochloride 具有抗炎作用并抑制与肠易激综合征相关的应激性胃溃疡。

corticotropin-releasing factor receptor 1 (CRF1) antagonist

NGD9002 is a novel generation, topology 2 selective corticotropin releasing factor-1 (CRF-1) receptor antagonist agent.

BMS-665053 is a corticotropin-releasing factor-1 (CRF1) receptor antagonist (IC50 = 1.0 nM). BMS-665053)11 is a potent inhibitor of CRF-stimulated cyclic adenosine monophosphate (cAMP) production in human Y-79 retinoblastoma cells (IC50 = 4.9 nM). In addi

BMS-764459 is a potent antagonist of corticotropin-releasing factor/hormone receptor 1 (CRHR-1).

E2508 is a selective antagonist of corticotropin-releasing factor 1 receptor.

NBI-30545 is a potent corticotropin-releasing factor-1 antagonist with sufficient lipophilicity and water solubility for the treatment of stress disorders.

Urocortin III is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin II , frog sauvagine, and piscine urotensin I.1 Human urocortin III shares 90, 40, 37, and 21% identity to mouse urocortin III , mouse urocortin II , human urocortin , and mouse urocortin, respectively. Urocortin III selectively binds to type 2 CRF receptors (Kis = 21.7, 13.5, and >100 nM for rat CRF2α, rat CRF2β, and human CRF1, respectively). It stimulates cAMP production in CHO cells expressing rat CRF2α and mouse CRF2β (EC50s = 0.16 and 0.12 nM, respectively) as well as cultured anterior pituitary cells expressing endogenous CRF2β. Urocortin III is co-released with insulin to potentiate glucose-stimulated somatostatin release in vitro in human pancreatic β-cells.2 In vivo, urocortin III reduces food intake in a dose- and time-dependent manner in mice with a minimum effective dose (MED) of 0.3 nmol/animal.3 It increases swimming time in a forced swim test in mice, indicating antidepressant-like activity.4References1. Lewis, K., Li, C., Perrin, M.H., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98(13), 7570-7575 (2001).2. van der Meulen, T., Donaldson, C.J., Cáceres, E., et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat. Med. 21(7), 769-776 (2015).3. Pelleymounter, M.A., Joppa, M., Ling, N., et al. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 25(4), 659-666 (2004).4. Tanaka, M., Kádár, K., Tóth, G., et al. Antidepressant-like effects of urocortin 3 fragments. Brain Res. Bull. 84(6), 414-418 (2011). Urocortin III is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin II , frog sauvagine, and piscine urotensin I.1 Human urocortin III shares 90, 40, 37, and 21% identity to mouse urocortin III , mouse urocortin II , human urocortin , and mouse urocortin, respectively. Urocortin III selectively binds to type 2 CRF receptors (Kis = 21.7, 13.5, and >100 nM for rat CRF2α, rat CRF2β, and human CRF1, respectively). It stimulates cAMP production in CHO cells expressing rat CRF2α and mouse CRF2β (EC50s = 0.16 and 0.12 nM, respectively) as well as cultured anterior pituitary cells expressing endogenous CRF2β. Urocortin III is co-released with insulin to potentiate glucose-stimulated somatostatin release in vitro in human pancreatic β-cells.2 In vivo, urocortin III reduces food intake in a dose- and time-dependent manner in mice with a minimum effective dose (MED) of 0.3 nmol/animal.3 It increases swimming time in a forced swim test in mice, indicating antidepressant-like activity.4 References1. Lewis, K., Li, C., Perrin, M.H., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98(13), 7570-7575 (2001).2. van der Meulen, T., Donaldson, C.J., Cáceres, E., et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat. Med. 21(7), 769-776 (2015).3. Pelleymounter, M.A., Joppa, M., Ling, N., et al. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 25(4), 659-666 (2004).4. Tanaka, M., Kádár, K., Tóth, G., et al. Antidepressant-like effects of urocortin 3 fragments. Brain Res. Bull. 84(6), 414-418 (2011).

Urocortin II is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin III , frog sauvagine, and piscine urotensin I.1 Mouse urocortin II shares 34 and 42% sequence homology with rat CRF and urocortin . It is expressed in mouse paraventricular, supraoptic, and arcuate nuclei of the hypothalamus, the locus coeruleus, and in motor nuclei of the brainstem and spinal ventral horn. Urocortin II selectively binds to CRF1 over CRF2 receptors (Kis = 0.66 and >100 nM, respectively) and induces cAMP production in CHO cells expressing CRF2 (EC50 = 0.14 nM). In vivo, urocortin II suppresses nighttime food intake by 35% in rats when administered intracerebroventricularly at a dose of 1 μg. Urocortin II (0.1 and 0.5 μg, i.c.v) stimulates fecal pellet output, increases distal colonic transit, and inhibits gastric emptying in mice.2References1. Reyes, T.M., Lewis, K., Perrin, M.H., et al. Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. U.S.A. 98(5), 2843-2848 (2001).2. Martinez, V., Wang, L., Million, M., et al. Urocortins and the regulation of gastrointestinal motor function and visceral pain. Peptides 25(10), 1733-1744 (2004). Urocortin II is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin III , frog sauvagine, and piscine urotensin I.1 Mouse urocortin II shares 34 and 42% sequence homology with rat CRF and urocortin . It is expressed in mouse paraventricular, supraoptic, and arcuate nuclei of the hypothalamus, the locus coeruleus, and in motor nuclei of the brainstem and spinal ventral horn. Urocortin II selectively binds to CRF1 over CRF2 receptors (Kis = 0.66 and >100 nM, respectively) and induces cAMP production in CHO cells expressing CRF2 (EC50 = 0.14 nM). In vivo, urocortin II suppresses nighttime food intake by 35% in rats when administered intracerebroventricularly at a dose of 1 μg. Urocortin II (0.1 and 0.5 μg, i.c.v) stimulates fecal pellet output, increases distal colonic transit, and inhibits gastric emptying in mice.2 References1. Reyes, T.M., Lewis, K., Perrin, M.H., et al. Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. U.S.A. 98(5), 2843-2848 (2001).2. Martinez, V., Wang, L., Million, M., et al. Urocortins and the regulation of gastrointestinal motor function and visceral pain. Peptides 25(10), 1733-1744 (2004).